Actinium-225 (Ac-225) Radiopharmaceuticals FDA Perspective . . . Actinium-225 • Physical t 1 2 – 9 92 days • Increasing clinical trials for radiopharmaceuticals containing Ac -225 for targeted alpha therapy • Availability of Ac -225 – For Ac -225 radiopharmaceuticals – For producing other isotopes (e g , 213 Bi) www fda gov
CHAPTER TWO ACTINIUM - Springer actinium X (also referred to as ‘‘emanium X”), now known as 223Ra, and showed it to be the direct source of the actinium emanation and its active deposit The following year, Hahn (1906a,b) discovered radioactinium (227Th), the immediate descendant of actinium and the parent of actinium X
Actinium-225 Production and the Future Needs for Labeled Drugs As the R D and the clinical interest for Actinium-225 labeled molecules increases, questions regarding future availability of industrial-scale quantities of this isotope cast doubt on the marketing viability of 225 Ac-labeled drugs
Radiopharmaceutical quality control considerations for . . . Actinium-225 (225Ac) produces four a-particles through its decay and is among the most attractive radionuclides for use in targeted radiotherapy applications However, supply issues for this isotope have limited availability and increased cost for research and translation
Accelerating Production of Non-Carrier Added Actinium-225 (n . . . Non-Carrier Added Actinium-225 (n c a Ac-225) INTRODUCTION Actinium has a pedigree leading back to the most famous researchers of radioactivity, Marie and Pierre Curie Actinium was first discovered by Andre Debierne in pitchblende residues left by the Curies in 1899 1 There remains some controversy